~~<i id='5C20F48C7A'><strike id='5C20F48C7A'><tt id='5C20F48C7A'><pre id='5C20F48C7A'></pre></tt></strike></i>~~

Home» knowledge» entertainment

entertainment

author：fashion 2025-09-30 03:23:13 Page View：36712

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tornado touches down near Chicago's O'Hare airport amid extreme weather nationwide
Next article： Wildfire smoke exposes gaps in outdoor worker protections

explore

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

Superbugs, antibiotic resistance get scrutiny in congress

Alabspecialistpointsoutexamplesofbacterialgrowth.(APPhoto/OlegPopov)OlegPopov/APMelanieLawrencedoesn

Alkermes shareholders re

MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

Why we need to separate burnout from moral injury in health care

APUGOMES/AFPviaGettyImagesInthenewbook“IfIBetrayTheseWords,”Itellthestory,withSimonTalbot,ofRitaGall